SwePub
Sök i LIBRIS databas

  Utökad sökning

L773:1062 3590
 

Sökning: L773:1062 3590 > (2024) > In Vitro Cytotoxic,...

In Vitro Cytotoxic, Genotoxic, Embryotoxic and Oxidative Damage Potentials by Empagliflozin

Cadirci, Kenan (författare)
Ataturk Univ, Fac Med, Dept Med Biol, Erzurum, Turkiye.
Turkez, Hasan (författare)
Ataturk Univ, Fac Med, Dept Med Biol, Erzurum, Turkiye.
Tozlu, Ozlem Ozdemir (författare)
Erzurum Tech Univ, Fac Sci, Dept Mol Biol & Genet, Erzurum, Turkiye.
visa fler...
Yapca, Omer Erkan (författare)
Ataturk Univ, Fac Med, Dept Obstet & Gynecol, Erzurum, Turkiye.
Bayrak, Muharrem (författare)
Hlth Sci Univ, Erzurum Reg Training & Res Hosp, Dept Internal Med, Erzurum, Turkiye.
Emsen, Bugrahan (författare)
Karamanoglu Mehmetbey Univ, Kamil Ozdag Fac Sci, Dept Biol, Karaman, Turkiye.
Mardinoglu, Adil (författare)
KTH,Systembiologi,Science for Life Laboratory, SciLifeLab,Kings Coll London, Fac Dent Oral & Craniofacial Sci, Ctr Host Microbiome Interact, London SE1 9RT, England.
visa färre...
Ataturk Univ, Fac Med, Dept Med Biol, Erzurum, Turkiye Erzurum Tech Univ, Fac Sci, Dept Mol Biol & Genet, Erzurum, Turkiye. (creator_code:org_t)
Pleiades Publishing Ltd, 2024
2024
Engelska.
Ingår i: Biology Bulletin of the Russian Academy of Science. - : Pleiades Publishing Ltd. - 1062-3590 .- 1608-3059. ; 51:2, s. 243-250
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Empagliflozin (EMPA) is a potent, competitive and selective sodium glucose cotransporter-2 (SGLT-2) inhibitor that ameliorates blood glucose with the insulin-independent manner. EMPA reduces weight and blood pressure of patients with type 2 diabetes mellitus (T2DM) without developing hypoglycemic risk. To the best of our knowledge, its safety profiling has not been evaluated on human blood cell cultures yet. Again, the embryotoxicity potential by EMPA is still unclear. Therefore, in this investigation we aimed to evaluate the in vitro cytotoxic, genotoxic and embryotoxic damage potential as well as antioxidative/oxidative effects by EMPA in cultured human blood and human pluripotent embryonal carcinoma NT2 cells for the first time. Cell cultures (n = 5) were exposed to different concentrations ranging from 3.25 to 100 mg/L of EMPA for 48 and 72 h. Cell viability was measured by using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and lactate dehydrogenase (LDH) release assays. The alterations in antioxidant/oxidant activity were monitored via measuring the total antioxidant capacity (TAC) and total oxidative stress (TOS) levels. For evaluating the genotoxicity of EMPA chromosomal aberration (CA) assay was performed. The present results revealed that EMPA did not induce cytotoxic or genotoxic damage on healthy human blood cells. Moreover, EMPA exerted non-embryotoxic property and supported antioxidative capacity and decreased the oxidative stress in cultured human blood cells. Our results supported the safe and advantageous use of EMPA for the treatment of T2DM.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Medicinska och farmaceutiska grundvetenskaper (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Basic Medicine (hsv//eng)

Nyckelord

cytotoxicity
empagliflozin
genotoxicity
embryotoxicity
total antioxidant capacity
total oxidative stress

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy